Method
Blood and skin samples from COVID-19 patients suffering from
maculopapular drug rashes (COVID-MDR), healthy controls,
non-COVID-19—related patients with drug rash with eosinophilia and
systemic symptoms (DRESS), and MDR were analyzed. We utilized imaging
mass cytometry (IMC) to characterize the cellular infiltrate in skin
biopsies. Furthermore, RNA sequencing transcriptome of skin biopsy
samples and high-throughput multiplexed proteomic profiling of serum
were performed.